---
title: "Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with Amoytop"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291839191.md"
description: "Aligos Therapeutics received a $25 million upfront payment from Amoytop for an exclusive Greater China license of pevifoscorvir sodium. The deal includes up to $420 million in potential milestones and tiered royalties. Aligos retains global rights outside Greater China. The NMPA CDE granted Breakthrough Therapy Designation, enabling priority review."
datetime: "2026-07-06T20:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291839191.md)
  - [en](https://longbridge.com/en/news/291839191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291839191.md)
generator: "portal-rs"
---

# Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with Amoytop

-   Aligos received an upfront payment of USD 25 million from an exclusive Greater China license for pevifoscorvir sodium with Amoytop. \* Deal includes up to USD 420 million in clinical, regulatory, sales milestones; tiered high single-digit royalties on net sales. \* Aligos keeps development and commercialization rights outside Greater China, including the U.S. and Europe. \* China’s NMPA CDE granted Breakthrough Therapy Designation for pevifoscorvir sodium, enabling priority NDA review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607061605PRIMZONEFULLFEED9757506) on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [688278.CN](https://longbridge.com/en/quote/688278.CN.md)

## Related News & Research

- [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [Oncoinvent publishes corporate presentation on Radspherin alpha therapy for peritoneal metastases](https://longbridge.com/en/news/296475294.md)
- [Bausch + Lomb Advancing Two First-In-Class Eye Health Therapies Based On Trial Results](https://longbridge.com/en/news/296827543.md)
- [WorldQuant discloses net short position in DBV Technologies](https://longbridge.com/en/news/296625918.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**